Some New Findings in the Pathogenesis of Myeloproliferative Disorders and New Insight into More Effective Treatment
Authors:
P. Klener
Authors‘ workplace:
1. interní klinika 1. LF UK a VFN a ÚHKT, Praha
Published in:
Čas. Lék. čes. 2006; 145: 4-8
Category:
Editorial
Overview
Advances in molecular biology and genomics enabled more detailed view on the pathogenesis of myeloproliferative disorders, which are considered to be a diseases of hematopoietic stem cell. The autor provides an brief overview of the genetic alterations, leading to the chronic myeloid leukemia, myelodysplastic syndrome and acute myeloid leukemia. In the second part, molecular targeted therapies that have been developed based on these insights are reviewed. These are particularly methods preventing increased proliferation such as inhibition of tyrosinkinases (imatinib, dasatinib), inhibitions of farnesyltransferase (tipifarnib), inhibition of angiogenesis (bevacizumab, vatalanib), induction of diferentiation (hypomethylating agenents) and induction of apoptosis (bortezomib). More detailed information is given on some novel drugs which are currently in clinical trials.
Key words:
leukemic hematopoiesis, myeloproliferative disorders, novel therapies.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Impact Factor – Good Servant, but a Bad Master
- Acute Toxicity of High Dose Interstitial Brachytherapy Boost in Prostate Cancer
- Abuse of Buprenorphine Becomes a Problem of the Czech Republic
- High Dose Therapy with Autologous Stem Cell Transplantation in Patients with Hodgkin’s Lymphoma: Long Term Follow-up in Patients Treated in One Center